BR112015026017A2 - construtos de proteínas mitocondriais e usos dos mesmos - Google Patents
construtos de proteínas mitocondriais e usos dos mesmosInfo
- Publication number
- BR112015026017A2 BR112015026017A2 BR112015026017A BR112015026017A BR112015026017A2 BR 112015026017 A2 BR112015026017 A2 BR 112015026017A2 BR 112015026017 A BR112015026017 A BR 112015026017A BR 112015026017 A BR112015026017 A BR 112015026017A BR 112015026017 A2 BR112015026017 A2 BR 112015026017A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein constructs
- mitochondrial protein
- disclosed
- mitochondrial
- constructs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0091—Oxidoreductases (1.) oxidizing metal ions (1.16)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1018—Carboxy- and carbamoyl transferases (2.1.3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
Abstract
resumo construtos de proteínas mitocondriais e usos dos mesmos divulgadas são as construções da proteína de fusão novas compreendendo uma proteína mitocondrial funcional, que podem entrar na mitocôndria nas células intactas. são divulgados ainda métodos de tratamento de distúrbios mitocondriais pelas proteínas de fusão divulgadas e composições para as mesmas. 1/1
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361811934P | 2013-04-15 | 2013-04-15 | |
US201361869981P | 2013-08-26 | 2013-08-26 | |
US14/034,224 US8912147B2 (en) | 2013-04-15 | 2013-09-23 | Mitochondrial proteins constructs and uses thereof |
PCT/IL2014/050354 WO2014170896A2 (en) | 2013-04-15 | 2014-04-10 | Mitochondrial proteins constructs and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015026017A2 true BR112015026017A2 (pt) | 2017-10-17 |
Family
ID=51686951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015026017A BR112015026017A2 (pt) | 2013-04-15 | 2014-04-10 | construtos de proteínas mitocondriais e usos dos mesmos |
Country Status (13)
Country | Link |
---|---|
US (1) | US8912147B2 (pt) |
EP (1) | EP2986629B1 (pt) |
JP (1) | JP2016520557A (pt) |
KR (1) | KR20150143778A (pt) |
AU (1) | AU2014255313A1 (pt) |
BR (1) | BR112015026017A2 (pt) |
CA (1) | CA2909276A1 (pt) |
EA (1) | EA201501028A1 (pt) |
MD (1) | MD20150109A2 (pt) |
MX (1) | MX2015014424A (pt) |
PE (1) | PE20151774A1 (pt) |
SG (1) | SG11201508313TA (pt) |
WO (1) | WO2014170896A2 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109072217A (zh) * | 2016-04-12 | 2018-12-21 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 用于治疗与mcm缺陷相关的病症的甲基丙二酰辅酶a变位酶(mcm)融合构建体 |
GB201721833D0 (en) * | 2017-12-22 | 2018-02-07 | Cancer Research Tech Ltd | Fusion proteins |
US11685906B2 (en) * | 2018-12-06 | 2023-06-27 | Arcturus Therapeutics, Inc. | Compositions and methods for treating ornithine transcarbamylase deficiency |
WO2020118239A1 (en) * | 2018-12-06 | 2020-06-11 | Arcturus Therapeutics, Inc. | Modified proteins and associated methods of treatment |
CN110003345A (zh) * | 2019-04-03 | 2019-07-12 | 天津师范大学 | 一种抗迟缓爱德华氏菌的TAT-EseD重组蛋白及用途 |
US20220378869A1 (en) | 2019-07-18 | 2022-12-01 | Larimar Therapeutics, Inc. | Use of frataxin for treating leigh syndrome, french canadian type |
WO2021021931A1 (en) * | 2019-07-29 | 2021-02-04 | The Trustees Of Indiana University | Materials and methods for treating friedreich's ataxia |
EP4126228A2 (en) | 2020-03-26 | 2023-02-08 | Larimar Therapeutics, Inc. | Molecules for organelle-specific protein delivery |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8283444B2 (en) * | 2003-10-24 | 2012-10-09 | Wake Forest University | Non-viral delivery of compounds to mitochondria |
PL2300614T3 (pl) | 2008-02-04 | 2016-04-29 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Sposoby i kompozycje do leczenia zaburzeń mitochondrialnych |
-
2013
- 2013-09-23 US US14/034,224 patent/US8912147B2/en not_active Expired - Fee Related
-
2014
- 2014-04-10 KR KR1020157032681A patent/KR20150143778A/ko not_active Application Discontinuation
- 2014-04-10 JP JP2016507115A patent/JP2016520557A/ja active Pending
- 2014-04-10 MD MDA20150109A patent/MD20150109A2/ro not_active Application Discontinuation
- 2014-04-10 EP EP14723894.3A patent/EP2986629B1/en active Active
- 2014-04-10 AU AU2014255313A patent/AU2014255313A1/en not_active Abandoned
- 2014-04-10 WO PCT/IL2014/050354 patent/WO2014170896A2/en active Application Filing
- 2014-04-10 BR BR112015026017A patent/BR112015026017A2/pt not_active Application Discontinuation
- 2014-04-10 MX MX2015014424A patent/MX2015014424A/es unknown
- 2014-04-10 CA CA2909276A patent/CA2909276A1/en not_active Abandoned
- 2014-04-10 PE PE2015002144A patent/PE20151774A1/es not_active Application Discontinuation
- 2014-04-10 SG SG11201508313TA patent/SG11201508313TA/en unknown
- 2014-04-10 EA EA201501028A patent/EA201501028A1/ru unknown
Also Published As
Publication number | Publication date |
---|---|
EA201501028A1 (ru) | 2016-04-29 |
CA2909276A1 (en) | 2014-10-23 |
MX2015014424A (es) | 2016-05-18 |
US20140308262A1 (en) | 2014-10-16 |
PE20151774A1 (es) | 2015-12-20 |
JP2016520557A (ja) | 2016-07-14 |
WO2014170896A2 (en) | 2014-10-23 |
SG11201508313TA (en) | 2015-11-27 |
EP2986629B1 (en) | 2017-11-08 |
US8912147B2 (en) | 2014-12-16 |
AU2014255313A1 (en) | 2015-09-10 |
MD20150109A2 (ro) | 2016-03-31 |
WO2014170896A3 (en) | 2014-12-31 |
EP2986629A2 (en) | 2016-02-24 |
KR20150143778A (ko) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015026017A2 (pt) | construtos de proteínas mitocondriais e usos dos mesmos | |
CL2022000036A1 (es) | Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261) | |
BR112015021618A2 (pt) | métodos e composições para controle de ervas daninhas | |
UY37463A (es) | Proteínas de unión | |
CO2018000648A2 (es) | Compuestos de piridina sustituidos, intermediarios para su preparación y composiciones que los comprenden | |
BR112018072946A2 (pt) | proteínas de fusão a gdf15 e usos das mesmas | |
BR112016025516A2 (pt) | composições para controle de mosquito e usos das mesmas | |
BR112016002199A2 (pt) | Proteína anti-garp e usos da mesma | |
CO7121348A2 (es) | Proteínas de fusión de interleuquina-2 y usos de las mismas | |
BR112015022191A2 (pt) | compostos heteroarila, seu uso e composição que os compreende | |
UY35407A (es) | ?PROTEÍNAS DE FUSIÓN COMPRENDIENDO PORCIONES PDGF y VEGF DE UNIÓN Y MÉTODOS PARA SU USO?. | |
BR112015027377A8 (pt) | Compostos oligoméricos com grupos de conjugado, composições compreendendo os referidos compostos e usos dos mesmos | |
BR112016015105A2 (pt) | Conjugados var2csa-droga | |
BR112017005997A2 (pt) | método | |
BR112015004467A2 (pt) | método para controlar a heterogeneidade de proteínas | |
BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
BR112015028278A2 (pt) | processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos | |
BR112017013576A2 (pt) | produção melhorada de lipídios de núcleo em leveduras oleaginosas | |
BR112016010072A8 (pt) | conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado | |
BR112017013574A2 (pt) | conjugados de aminoácido e peptídeo e usos dos mesmos | |
AR092879A1 (es) | Proteinas de fusion de g3p como agentes de union a amiloide | |
BR112015019662A2 (pt) | uso de protioconazol para induzir respostas de defesa do hospedeiro | |
BR112015026388A2 (pt) | métodos e composições para cicatrização de feridas | |
UY36617A (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer | |
BR112018070139A2 (pt) | expressão de proteínas em bactérias gram-negativas em que a razão entre o volume periplasmático e o volume citoplasmático é entre 0,5:1 e 10:1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |